Sign in to view content

Safety and Efficacy of Switching to Biosimilar Ranibizumab in Eyes Initially Treated With Reference Ranibizumab for nAMD, DME, or RVO

Nikhil K Bommakanti, MD

Video
Published 2024

Related

Use of Anti – VEGF Therapy for ROP: When and How
Updates from the Field
2017
Percentage of Patients Maintained on Quarterly Anti-VEGF Dosing for the Treatment of Neovascular Age-Related Macular Degeneration
David A. Eichenbaum, MD, FASRS
Updates from the Field
2018
Abicipar Phase 2 MAPLE Trial: Evaluation of All Patients With Post-Injection Inflammation
Tarek S. Hassan, MD, FASRS
Annual Meeting Talks
2020

Category: AMD-Neovascular

See more